Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 104

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 104
---
, often involving multiple treatment arms to isolate the contribution of each agent. Regulatory agencies
may request mechanistic justification and additional data to ensure that the benefit is not solely attributable to the approved partner
drug.

From a marketing perspective, positioning
a combination therapy is also more challenging. Uptake depends on alignment with established treatment paradigms, pricing relative to
existing regimens, and reimbursement policies. Physicians may hesitate to adopt combinations unless clear superiority in outcomes is
demonstrated.

IP Protection.

The ATI Receptor Blockers technology is covered
by patent applications listed below, which, subject to our exercising our option to obtain the license, will be the subject of an exclusive
to us by Yissum.

Title: Liposomal Formulations Comprising AT1 Receptor Blockers (ARB) and Uses Thereof (Composition matter and use claimed)

| ** | Note: this                                                                               
 application was abandoned and divisional application in CN was filed. The divisional has 
 not been published yet (as of Sept 20th, 2025)                                           |

<div align='center'>67</div>

References:

| 1. | Keith SW, Gerber DE, Raghavan D, Galsky MD, Lin J, Wang L, et al. Angiotensin blockade therapy 
 and survival in pancreatic cancer. BMC Cancer. 2022;22(1):920. doi:10.1186/s12885-022-09200-4  |

| 2. | Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, Yamamoto K, Arizumi T, Hamada S,           
 Miyabayashi K, Mizuno S, Kawakubo K, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K.     
 Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced 
 pancreatic cancer: GECA1. Cancer Science. 2012;103(8):1489-92. doi:10.1111/j.1349-7006.2012.02311.x     |

| 3. | Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting           
 enzyme inhibitors and angiotensin II type 1 receptor